MEP10408A - Platinum derivative pharmaceutical formulations - Google Patents

Platinum derivative pharmaceutical formulations

Info

Publication number: MEP10408A
Authority: ME; Montenegro
Prior art keywords: pharmaceutical formulations; platinum derivative; derivative pharmaceutical; pharmaceutically acceptable; present
Prior art date: 2001-12-06

Application number

MEP-104/08A

Other languages

Bosnian (bs)

English (en)

Croatian (hr)

Inventor

Sara Lauria

Alessandro Martini

Cristina Ciocca

Original Assignee

Pharmacia Italia Spa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-12-06

Filing date

2002-11-22

Publication date

2011-02-10

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21744006&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MEP10408(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2002-11-22 Application filed by Pharmacia Italia Spa filed Critical Pharmacia Italia Spa

2011-02-10 Publication of MEP10408A publication Critical patent/MEP10408A/xx

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Dermatology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Oil, Petroleum & Natural Gas (AREA)
Oncology (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)

MEP-104/08A 2001-12-06 2002-11-22 Platinum derivative pharmaceutical formulations MEP10408A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US10/010,122 US6476068B1 (en)	2001-12-06	2001-12-06	Platinum derivative pharmaceutical formulations
PCT/EP2002/013146 WO2003047587A1 (en)	2001-12-06	2002-11-22	Platinum derivative pharmaceutical formulations

Publications (1)

Publication Number	Publication Date
MEP10408A true MEP10408A (en)	2011-02-10

Family

ID=21744006

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MEP-104/08A MEP10408A (en)	2001-12-06	2002-11-22	Platinum derivative pharmaceutical formulations

Country Status (41)

Country	Link
US (3)	US6476068B1 (is)
EP (1)	EP1453517B1 (is)
JP (1)	JP2005515202A (is)
KR (1)	KR100941210B1 (is)
CN (1)	CN100540006C (is)
AP (1)	AP1760A (is)
AR (1)	AR037629A1 (is)
AT (1)	ATE317260T1 (is)
AU (1)	AU2002352105B2 (is)
BR (1)	BR0214757A (is)
CA (1)	CA2468916C (is)
CO (1)	CO5580776A2 (is)
CR (1)	CR7362A (is)
CY (1)	CY1105608T1 (is)
DE (1)	DE60209145T2 (is)
DK (1)	DK1453517T3 (is)
EA (1)	EA008090B1 (is)
EC (1)	ECSP045140A (is)
ES (1)	ES2258661T3 (is)
GE (1)	GEP20063895B (is)
HR (1)	HRP20040514A2 (is)
HU (1)	HUP0402217A3 (is)
IL (2)	IL162348A0 (is)
IS (1)	IS2580B (is)
MA (1)	MA27153A1 (is)
ME (1)	MEP10408A (is)
MX (1)	MXPA04005423A (is)
MY (1)	MY134422A (is)
NO (1)	NO330159B1 (is)
NZ (1)	NZ533383A (is)
OA (1)	OA12739A (is)
PL (1)	PL206755B1 (is)
PT (1)	PT1453517E (is)
RO (1)	RO121509B1 (is)
RS (1)	RS50360B (is)
SI (1)	SI21493A (is)
TN (1)	TNSN04104A1 (is)
TW (1)	TW200409640A (is)
UA (1)	UA77728C2 (is)
WO (1)	WO2003047587A1 (is)
ZA (1)	ZA200404525B (is)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20040186172A1 (en) *	2001-07-02	2004-09-23	Houssam Ibrahim	Oxaliplatin active substance with a very low content of oxalic acid
CA2388352A1 (en) *	2002-05-31	2003-11-30	Voiceage Corporation	A method and device for frequency-selective pitch enhancement of synthesized speed
US20040022842A1 (en) *	2002-06-03	2004-02-05	Mebiopharm Co., Ltd.	Liposome preparations containing oxaliplatin
DE10314377A1 (de) *	2003-03-28	2004-10-07	Stada Arzneimittel Ag	Gebrauchsfertige Oxaliplatin-Lösungen
GB2441445B (en) *	2003-08-28	2008-04-23	Mayne Pharma Ltd	Acid containing oxaliplatin formulation
CN101022790A (zh) *	2003-08-28	2007-08-22	梅恩医药有限公司	含有酸的奥沙利铂制剂
EP1682529A4 (en) *	2003-11-07	2010-06-30	Novartis Vaccines & Diagnostic	PROCESS FOR SYNTHESIS OF CHINOLINONE COMPOUNDS
RU2273475C2 (ru) *	2004-04-06	2006-04-10	Государственное учреждение системы высшего и послевузовского профессионального образования "Сибирский государственный медицинский университет" (ГУ СВ ПО СибГМУ)	Способ лечения диссеминированного колоректального рака
US7795205B2 (en) *	2004-04-12	2010-09-14	Canyon Pharmaceuticals, Inc.	Methods for effecting regression of tumor mass and size in a metastasized pancreatic tumor
EA011573B1 (ru) *	2004-06-09	2009-04-28	Тайхо Фармасьютикал Ко., Лтд.	Препарат, потенцирующий противоопухолевый эффект, противоопухолевый препарат и способ лечения рака
TW200617014A (en) *	2004-07-12	2006-06-01	Sicor Inc	Cis-diiodo-(trans-l-1,2-cyclohexanediamine) platinum (Ⅱ) complex and processes for preparing high purity oxaliplatin
US20060063833A1 (en) *	2004-09-22	2006-03-23	Edgar Schridde	Ready-to-use oxaliplatin solutions
US20060063720A1 (en) *	2004-09-22	2006-03-23	Edgar Schridde	Oxaliplatin solution concentrate
DE102004052877B4 (de) *	2004-11-02	2008-06-19	Ebewe Pharma Ges.M.B.H. Nfg.Kg	Stabile wässrige Formulierungen eines Platin-Derivats
CN1311818C (zh) *	2004-11-22	2007-04-25	山东蓝金生物工程有限公司	一种抗实体肿瘤的药物组合物
DE102004063764A1 (de) *	2004-12-29	2006-07-13	Hexal Ag	Kunststoff-Flasche für Oxaliplatin
JP2006248978A (ja)	2005-03-10	2006-09-21	Mebiopharm Co Ltd	新規なリポソーム製剤
EP1879568B1 (en) *	2005-03-28	2009-05-06	Dabur Pharma Limited	Stable pharmaceutical compositions of platinum (ii) antitumour agents
EP1885187B1 (en) *	2005-05-13	2013-09-25	Novartis AG	Methods for treating drug resistant cancer
DE102005038347A1 (de) *	2005-08-11	2007-02-15	Hexal Ag	Herstellung einer Oxaliplatin-Lösung und Behälter sowie Behälter-Set mit der Lösung
WO2007029268A2 (en) *	2005-09-05	2007-03-15	Dabur Pharma Limited	Stable oxaliplatin formulation
EP2772257A1 (en) *	2005-11-29	2014-09-03	Novartis AG	Formulations of quinolinones
US20090076139A1 (en) *	2007-09-19	2009-03-19	Protia, Llc	Deuterium-enriched oxalplatin
WO2009087660A1 (en)	2007-11-12	2009-07-16	Intas Pharmaceuticals Limited	Stable oxaliplatin composition for parenteral administration
JP5579083B2 (ja) *	2008-02-29	2014-08-27	イーグル・ファーマシューティカルズ・インコーポレーテッド	そのまま使用できるトポテカン溶液
US9023834B2 (en) *	2008-11-13	2015-05-05	Taigen Biotechnology Co., Ltd.	Lyophilization formulation
EP2481396A4 (en)	2009-09-21	2014-03-05	Jw Pharmaceutical Corp	OXALIPLATIN NANOPARTICLES AND MANUFACTURING METHOD THEREFOR
US9387152B2 (en)	2010-06-28	2016-07-12	The General Hospital Corporation	Blood substitutes and uses thereof
CN102274171A (zh) *	2011-08-04	2011-12-14	上海希迪制药有限公司	一种奥沙利铂注射剂
MX2015000813A (es)	2012-07-18	2015-09-07	Onyx Therapeutics Inc	Composiciones liposómicas de inhibidores de proteasoma basadas en epoxicetona.
JP5929607B2 (ja) *	2012-08-06	2016-06-08	ニプロ株式会社	オキサリプラチン製剤
CN102885765B (zh) *	2012-10-25	2013-11-06	哈药集团生物工程有限公司	一种盐酸伊立替康注射液及其制备方法
US10098813B2 (en) *	2014-09-03	2018-10-16	Sun Pharmaceutical Industries Limited	Perfusion dosage form
KR101683635B1 (ko)	2014-12-29	2016-12-09	가천대학교 산학협력단	락테이트 금속염을 포함하는 암 치료용 약학 조성물
FI4011377T3 (fi) *	2015-02-13	2025-01-07	Sun Pharmaceutical Ind Ltd	Suonensisäinen infuusioannosmuoto sisältäen pemetreksediä
KR102293907B1 (ko) *	2015-06-30	2021-08-26	한미약품 주식회사	이리노테칸 함유 경구용 고형제제 및 그 제조방법
ES2968415T3 (es)	2016-02-09	2024-05-09	Sun Pharmaceutical Ind Ltd	Sistema de perfusión
WO2018087720A1 (en)	2016-11-14	2018-05-17	Novartis Ag	Compositions, methods, and therapeutic uses related to fusogenic protein minion
SG11202006601VA (en)	2018-01-12	2020-08-28	Metimedi Pharmaceuticals Co Ltd	Methods of treating chronic inflammatory diseases
KR101998246B1 (ko)	2018-08-22	2019-07-10	주식회사 메타파인즈	금속이온에 결합된 이온화합물을 포함하는 암 치료용 약학 조성물

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS6041077B2 (ja)	1976-09-06	1985-09-13	喜徳喜谷	１，２‐ジアミノシクロヘキサン異性体のシス白金（２）錯体
US5041578A (en) *	1988-11-22	1991-08-20	Board Of Regents, The University Of Texas System	Water soluble 1,2-diaminocyclohexane platinum (IV) complexes as antitumor agents
PT101061B (pt)	1991-11-15	1999-07-30	Smithkline Beckman Corp	Composicoes farmaceuticas contendo anagolos da camptotecina e um composto de coordenacao de platina e seu uso na inibicao do crescimento de celulas tumorais
JPH0776230B2 (ja)	1992-01-13	1995-08-16	田中貴金属工業株式会社	白金化合物の製造方法
JPH06287021A (ja)	1992-04-22	1994-10-11	Tanaka Kikinzoku Kogyo Kk	光学活性な白金錯化合物の光学的分割方法
JP2673331B2 (ja)	1993-01-12	1997-11-05	田中貴金属工業株式会社	光学的に高純度なシス―オキザラート（トランス―１―１，２―シクロヘキサンジアミン）白金（▲ｉｉ▼）
WO1994012193A1 (fr)	1992-11-24	1994-06-09	Debiopharm S.A.	Combinaison de cisplatine avec l'oxaliplatine
DK0835657T3 (da) *	1992-11-27	2005-01-10	Mayne Pharma Usa Inc	Stabil, injicerbar paclitaxelsammensætning
JP3025602B2 (ja)	1993-05-21	2000-03-27	デビオファームエス．アー．	光学的に高純度なシス−オキザラート（トランス−ｌ−１，２−シクロヘキサンジアミン）白金（ＩＩ）錯体の製造方法
US5455270A (en) *	1993-08-11	1995-10-03	Bristol-Myers Squibb Co.	Stabilized solutions of platinum(II) antitumor agents
US5716988A (en)	1994-08-08	1998-02-10	Debiopharm S.A.	Pharmaceutically stable preparation of oxaliplatinum
EP1369116A1 (en)	1994-11-11	2003-12-10	Debiopharm S.A.	Oxalatoplatin and 5-fluorouracil for combination therapy of cancer
US5919816A (en)	1994-11-14	1999-07-06	Bionumerik Pharmaceuticals, Inc.	Formulations and methods of reducing toxicity of antineoplastic agents
JP3715650B2 (ja) *	1995-02-28	2005-11-09	喜徳喜谷	新規白金（ｉｖ）錯体、その製造方法及びそれを含む制癌剤
US5776959A (en)	1995-06-05	1998-07-07	Washington University	Anticonvulsant and anxiolytic lactam and thiolactam derivatives
JP3154399B2 (ja)	1996-07-04	2001-04-09	デビオファームエス．アー．	白金化合物の製造方法
EP0897389B1 (fr) *	1996-03-11	2002-07-03	Yoshinori Kidani	Complexes de platine dinucleaires, procede pour leur preparation et compositions pharmaceutiques en contenant
JP2001501173A (ja)	1996-08-23	2001-01-30	アルザコーポレイション	シスプラチン化合物を含有するリポソーム
US6056973A (en)	1996-10-11	2000-05-02	Sequus Pharmaceuticals, Inc.	Therapeutic liposome composition and method of preparation
KR100578705B1 (ko)	1997-02-05	2006-05-12	파마시아 앤드 업존 캄파니 엘엘씨	고불용성 백금 착체의 지질 복합체 및 리포좀
EP1014990B1 (en)	1997-03-07	2006-09-06	Sanofi-Aventis U.S. LLC	Antitumor combination of 3-amino-1,2,4-benzotriazine 1,4-dioxide/paclitaxel/platinum
GB9727523D0 (en)	1997-12-31	1998-02-25	Pharmacia & Upjohn Spa	Alpha-aminoamide derivatives useful as analgesic agents
GB9804013D0 (en) *	1998-02-25	1998-04-22	Sanofi Sa	Formulations
EP1121117B1 (fr)	1998-10-14	2002-06-05	Debiopharm S.A.	Conditionnement d'une preparation d'oxaliplatine
UA71985C2 (uk)	1999-08-30	2005-01-17	Дебіофарм С.А.	Стабільний фармацевтичний препарат оксаліплатини для парентерального введення та спосіб його одержання
AU2001240001A1 (en)	2000-03-08	2001-09-17	Bristol-Myers Squibb Company	Oral dosage form for administration of the combination of tegafur, uracil, folinic acid, and oxaliplatin and method of using the same
SE0003026D0 (sv) *	2000-08-25	2000-08-25	Kerstin Sunnerheim	Use for conifer sapling protection

2001
- 2001-12-06 US US10/010,122 patent/US6476068B1/en not_active Expired - Fee Related
2002
- 2002-08-22 US US10/225,607 patent/US6673805B2/en not_active Expired - Fee Related
- 2002-11-15 US US10/295,799 patent/US20030109515A1/en not_active Abandoned
- 2002-11-22 HR HR20040514A patent/HRP20040514A2/hr not_active Application Discontinuation
- 2002-11-22 JP JP2003548842A patent/JP2005515202A/ja not_active Withdrawn
- 2002-11-22 PT PT02787779T patent/PT1453517E/pt unknown
- 2002-11-22 ES ES02787779T patent/ES2258661T3/es not_active Expired - Lifetime
- 2002-11-22 IL IL16234802A patent/IL162348A0/xx unknown
- 2002-11-22 KR KR1020047008709A patent/KR100941210B1/ko not_active Expired - Fee Related
- 2002-11-22 OA OA1200400165A patent/OA12739A/en unknown
- 2002-11-22 EP EP02787779A patent/EP1453517B1/en not_active Expired - Lifetime
- 2002-11-22 AU AU2002352105A patent/AU2002352105B2/en not_active Ceased
- 2002-11-22 EA EA200400777A patent/EA008090B1/ru not_active IP Right Cessation
- 2002-11-22 AP APAP/P/2004/003055A patent/AP1760A/en active
- 2002-11-22 DK DK02787779T patent/DK1453517T3/da active
- 2002-11-22 CA CA002468916A patent/CA2468916C/en not_active Expired - Fee Related
- 2002-11-22 AT AT02787779T patent/ATE317260T1/de active
- 2002-11-22 NZ NZ533383A patent/NZ533383A/en not_active IP Right Cessation
- 2002-11-22 RS YUP-597/04A patent/RS50360B/sr unknown
- 2002-11-22 GE GE5607A patent/GEP20063895B/en unknown
- 2002-11-22 HU HU0402217A patent/HUP0402217A3/hu unknown
- 2002-11-22 WO PCT/EP2002/013146 patent/WO2003047587A1/en not_active Ceased
- 2002-11-22 ME MEP-104/08A patent/MEP10408A/xx unknown
- 2002-11-22 SI SI200220035A patent/SI21493A/sl not_active IP Right Cessation
- 2002-11-22 CN CNB028268431A patent/CN100540006C/zh not_active Expired - Fee Related
- 2002-11-22 UA UA20040705324A patent/UA77728C2/uk unknown
- 2002-11-22 PL PL370254A patent/PL206755B1/pl not_active IP Right Cessation
- 2002-11-22 BR BR0214757-2A patent/BR0214757A/pt not_active IP Right Cessation
- 2002-11-22 DE DE60209145T patent/DE60209145T2/de not_active Expired - Lifetime
- 2002-11-22 MX MXPA04005423A patent/MXPA04005423A/es active IP Right Grant
- 2002-11-22 RO ROA200400514A patent/RO121509B1/ro unknown
- 2002-12-04 MY MYPI20024553A patent/MY134422A/en unknown
- 2002-12-04 AR ARP020104679A patent/AR037629A1/es unknown
- 2002-12-05 TW TW091135278A patent/TW200409640A/zh unknown
2004
- 2004-06-03 IS IS7298A patent/IS2580B/is unknown
- 2004-06-03 IL IL162348A patent/IL162348A/en not_active IP Right Cessation
- 2004-06-04 EC EC2004005140A patent/ECSP045140A/es unknown
- 2004-06-04 MA MA27715A patent/MA27153A1/fr unknown
- 2004-06-04 CR CR7362A patent/CR7362A/es not_active Application Discontinuation
- 2004-06-04 TN TNP2004000104A patent/TNSN04104A1/fr unknown
- 2004-06-07 CO CO04053199A patent/CO5580776A2/es not_active Application Discontinuation
- 2004-06-08 ZA ZA200404525A patent/ZA200404525B/en unknown
- 2004-07-05 NO NO20042842A patent/NO330159B1/no not_active IP Right Cessation
2006
- 2006-05-04 CY CY20061100574T patent/CY1105608T1/el unknown

Also Published As

Publication number	Publication date
PL370254A1 (en)	2005-05-16
EA008090B1 (ru)	2007-02-27
AU2002352105A1 (en)	2003-06-17
OA12739A (en)	2006-06-30
PT1453517E (pt)	2006-06-30
NO20042842L (no)	2004-07-05
AP2004003055A0 (en)	2004-06-30
RO121509B1 (ro)	2007-10-30
SI21493A (sl)	2004-12-31
CA2468916A1 (en)	2003-06-12
IS7298A (is)	2004-06-03
HUP0402217A2 (hu)	2005-01-28
ECSP045140A (es)	2004-08-27
IL162348A0 (en)	2005-11-20
AP1760A (en)	2007-07-18
AU2002352105B2 (en)	2009-12-03
MXPA04005423A (es)	2004-10-11
US20030109515A1 (en)	2003-06-12
WO2003047587A1 (en)	2003-06-12
US20030109514A1 (en)	2003-06-12
KR100941210B1 (ko)	2010-02-10
MY134422A (en)	2007-12-31
US6476068B1 (en)	2002-11-05
HUP0402217A3 (en)	2005-11-28
EP1453517B1 (en)	2006-02-08
US6673805B2 (en)	2004-01-06
EA200400777A1 (ru)	2004-12-30
RS50360B (sr)	2009-11-10
ES2258661T3 (es)	2006-09-01
TNSN04104A1 (fr)	2006-06-01
CY1105608T1 (el)	2010-12-22
HK1072002A1 (zh)	2005-08-12
EP1453517A1 (en)	2004-09-08
TW200409640A (en)	2004-06-16
DE60209145T2 (de)	2006-10-26
CR7362A (es)	2009-02-12
NZ533383A (en)	2007-02-23
CN1612737A (zh)	2005-05-04
CN100540006C (zh)	2009-09-16
ATE317260T1 (de)	2006-02-15
NO330159B1 (no)	2011-02-28
IS2580B (is)	2010-02-15
UA77728C2 (en)	2007-01-15
YU59704A (sh)	2006-08-17
CA2468916C (en)	2009-01-20
PL206755B1 (pl)	2010-09-30
DE60209145D1 (de)	2006-04-20
DK1453517T3 (da)	2006-06-19
KR20050058278A (ko)	2005-06-16
MA27153A1 (fr)	2005-01-03
BR0214757A (pt)	2004-09-14
CO5580776A2 (es)	2005-11-30
IL162348A (en)	2010-11-30
AR037629A1 (es)	2004-11-17
HRP20040514A2 (en)	2004-10-31
JP2005515202A (ja)	2005-05-26
GEP20063895B (en)	2006-08-10
ZA200404525B (en)	2005-08-15

Publication	Publication Date	Title
MEP10408A (en)	2011-02-10	Platinum derivative pharmaceutical formulations
MXPA03009840A (es)	2004-04-02	Derivados de fenilurea sustituidos con carboxamida y metodo para la produccion de los mismos como farmacos.
TR200401029T4 (tr)	2004-06-21	Asilfenil-üre türevleri, imalat yöntemleri ve ilaç maddesi olarak kullanımları
ATE365720T1 (de)	2007-07-15	Agonisten von beta-adrenorezeptoren
NO20040547L (no)	2004-03-03	Amino-ftalazinonderivater aktive som kinaseinhibitorer, fremgangsmate for deres fremstilling og farmasoytiske sammensetninger inneholdende disse.
SE0301009D0 (sv)	2003-04-07	Novel compounds
ECSP034460A (es)	2003-03-10	Nuevos compuestos heterociclicos, su preparacion y su utilizacion como medicamentos, en especial como antibacterianos
SE0102438D0 (sv)	2001-07-05	New compounds
BR0308937A (pt)	2005-01-04	Compostos imidazo fundidos
BR0113838A (pt)	2003-06-03	Derivados de n-fenil-2-pirimidina-amina
MEP9309A (en)	2011-12-20	Novel oligosaccharides, preparation method and pharmaceutical compositions containing the same
SE0100569D0 (sv)	2001-02-20	New compounds
NO20005497D0 (no)	2000-11-01	Heterocykliske derivater som inhiberer faktor Xa
PT1272199E (pt)	2005-05-31	Terapias de combinacao com actividade de lesao vascular
DK1513800T3 (da)	2007-03-26	Benzoylureido-kanelsyrederivater, fremgangsmåde til deres anvendelse
SE0102440D0 (sv)	2001-07-05	New compound
AU3620799A (en)	1999-11-23	Heterocyclic derivatives which inhibit factor xa
NO20010940D0 (no)	2001-02-23	TAN-1057 derivater
NO20040821L (no)	2004-04-26	3-substituerte 6,7-dihydroksytetrahydroisokinolinderivater for andvendelse som antibakterielle midler.
MXPA04004443A (es)	2004-08-11	Derivados de pirazol.
SE0300457D0 (sv)	2003-02-19	Novel compounds
SE0102057D0 (sv)	2001-06-08	New Salts I
CY1106711T1 (el)	2012-05-23	Υποκατεστημενα παραγωγα προπανο-1,3-διαμινης και η φαρμακευτικη χρηση τους
DE60119514D1 (de)	2006-06-14	Amidderivate der 2-amino-3-hydroxy-4-tert-leucyl-amino-5-phenyl-pentansäure
HUP9801925A1 (hu)	2000-02-28	Nátrium/hidrogén-csere inhibítorok alkalmazása protozoák által okozott betegségek kezelésére alkalmas gyógyszerkészítmények előállítására